Management of women at increased risk for hereditary breast cancer

Breast Disease

Volumn 27, Issue 1, 2007, Pages 51-67

  Smith, Karen Lisa ^a   Isaacs, Claudine ^b  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

BRCA1; BRCA2; Hereditary breast cancer; Prevention; Screening

Indexed keywords

ANTIINFECTIVE AGENT; AROMATASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; PLATINUM COMPLEX; POLY(ADENOSINE DIPHOSPHATE RIBOSE); RALOXIFENE; TAMOXIFEN; TAXANE DERIVATIVE;

BREAST CANCER; BREAST EXAMINATION; BREAST SURGERY; CANCER GENETICS; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; FAMILIAL CANCER; GENE MUTATION; GENETIC COUNSELING; GENETIC HETEROGENEITY; HIGH RISK PATIENT; HUMAN; MALE BREAST; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 35048885951     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2007-27104     Document Type: Review

References (138)

1. G.L. Anderson, M. Limacher, A.R. Assaf et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial, JAMA 291 (2004), 1701-1712.
2. N. Andrieu, D.F. Easton, J. Chang-Claude et al., Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: A report from the EMBRACE, GENEPSO, GEOHEBON, and IBCCS Collaborators' Group, J Clin Oncol 24 (2006), 3361-3366.
3. N. Andrieu, D.E. Goldgar, D.F. Easton et al., Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS), J Natl Cancer Inst 98 (2006), 535-544.
4. A.C. Antoniou, A. Shenton, E.R. Maher et al., Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers, Breast Cancer Research 8 (2006), R72.
5. A. Ardern-Jones, R. Kenen and R. Eeles, Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40, Eur J Cancer Care 14 (2005), 272-281.
6. J. Benson, Is screening mammography safe for high-risk patients?, Lancet Oncol 7 (2006), 360-362.
7. V. Beral, Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet 362 (2003), 419-427.
8. J.L. Bernstein, S.N. Teraoka, E.M. John et al., The CHEK2* 1100delC allelic variant and risk of breast cancer: Screening results from the Breast Cancer Family Registry, Cancer Epidemiol Biomarkers Prev 15 (2006), 348-352.
9. J.M. Boyle, A. Spreadborough, M.J. Greaves et al., The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations, Br J Cancer 85 (2001), 293-296.
10. Breast Cancer Linkage Consortium, Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases, Lancet 349 (1997), 1505-1510.
11. C.T. Brekelmans, C. Seynaeve, C.C. Bartels et al., Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk, J Clin Oncol 19 (2001), 924-930.
12. C.T. Brekelmans, C. Seynaeve, M. Menke-Pluymers et al., Survival and prognostic factors in BRCA1-associated breast cancer, Ann Oncol 17 (2006), 391-400.
13. P.J. Bresser, C. Seynaeve, A.R. Van Gool et al., Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women, Plast Reconstr Surg 117 (2006), 1675-1682; discussion 1683-1674.
14. H.E. Bryant, N. Schultz, H.D. Thomas et al., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature 434 (2005), 913-917.
15. D.S. Buist, P.L. Porter, C. Lehman et al., Factors contributing to mammography failure in women aged 40-49 years, J Natl Cancer Inst 96 (2004), 1432-1440.
16. W. Burke, M. Daly, J. Garber et al., Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium, JAMA 277 (1997), 997-1003.
17. P.A. Carney, D.L. Miglioretti, B.C. Yankaskas et al., Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography, Ann Intern Med 138 (2003), 168-175.
18. R.T. Chlebowski, S.L. Hendrix, R.D. Langer et al., Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial, JAMA 289 (2003), 3243-3253.
19. R.C. Coombes, E. Hall, L.J. Gibson et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med 350 (2004), 1081-1092.
20. C.A. Cullinane, J. Lubinski, S.L. Neuhausen et al., Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers, Int J Cancer 117 (2005), 988-991.
21. S.R. Cummings, S. Eckert, K.A. Krueger et al., The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation, JAMA 281 (1999), 2189-2197.
22. J. Cuzick, J. Forbes, R. Edwards et al., First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial, Lancet 360 (2002), 817-824.
23. J. Cuzick, Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study), Recent Results Cancer Res 163 (2003), 96-103; discussion 264-106.
24. S.M. Domchek, T.M. Friebel, S.L. Neuhausen et al., Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study, Lancet Oncol 7 (2006 , 223-229.
25. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: An overview of the randomised trials, Lancet 351 (1998), 1451-1467.
26. R.F. Edlich, K.L. Winters, B.C. Faulkner et al., Risk-reducing mastectomy, J Long Term Eff Med Implants 16 (2006), 301-314.
27. H. Eerola, P. Vahteristo, L. Sarantaus et al., Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland, Int J Cancer 93 (2001), 368-372.
28. H. Eerola, P. Heikkila, A. Tamminen et al., Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families, Breast Cancer Res 7 (2005), R93-100.
29. A. Eisen, J. Lubinski, J. Klijn et al., Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study, J Clin Oncol 23 (2005), 7491-7496.
30. H. Farmer, N. McCabe, C.J. Lord et al., Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature 434 (2005), 917-921.
31. A. Finch, M. Beiner, J. Lubinski et al., Salpingooophorectomy and the risk of ovarian, fallopian tube, and peritonial cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296 (2006), 185-192.
32. B. Fisher, J.P. Costantino, D.L. Wickerham et al., Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 90 (1998), 1371-1388.
33. W.D. Foulkes, N. Wong, J.S. Brunet et al., Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer, Clin Cancer Res 3 (1997), 2465-2469.
34. W.D. Foulkes, I.M. Stefansson, P.O. Chappuis et al., Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer, J Natl Cancer Inst 95 (2003), 1482-1485.
35. M.H. Frost, D.J. Schaid, T.A. Sellers et al., Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy, JAMA 284 (2000), 319-324.
36. M.H. Frost, J.M. Slezak, N.V. Tran et al., Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance, J Clin Oncol 23 (2005), 7849-7856.
37. D. Goldfrank, S. Chuai, J.L. Bernstein et al., Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2 Cancer Epidemiol Biomarkers Prev 15 (2006), 2311-2313.
38. P.E. Goss and S. Sierra, Current perspectives on radiation-induced breast cancer, J Clin Oncol 16 (1998), 338-347.
39. K.D. Graves, B.N. Peshkin, C.H. Halbert et al., Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors, Breast Cancer Res Treat (2006): Epub ahead of print.
40. J. Gronwald, N. Tung, W.D. Foulkes et al., Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update, Int J Cancer 118 (2006), 2281-2284.
41. G. Haars, P.A. van Noord, C.H. van Gils et al., Measurements of breast density: No ratio for a ratio, Cancer Epidemiol Biomarkers Prev 14 (2005), 2634-2640.
42. B.G. Haffty, E. Harrold, A.J. Khan et al., Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status, Lancet 359 (2002), 1471-1477.
43. R.W. Haile, D.C. Thomas, V. McGuire et al., BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50, Cancer Epidemiol Biomarkers Prev 15 (2006), 1863-1870.
44. P. Hartge, N. Chatterjee, S. Wacholder et al., Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: Effects of reproductive history, Epidemiology 13 (2002), 255-261.
45. L.C. Hartmann, D.J. Schaid, J.E. Woods et al., Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer, N Engl J Med 340 (1999), 77-84.
46. L.C. Hartmann, T.A. Sellers, D.J. Schaid et al., Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers, J Natl Cancer Inst 93 (2001), 1633-1637.
47. N. Hoogerbrugge, P. Bult, L.M. de Widt-Levert et al., High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer, J Clin Oncol 21 (2003), 41-45.
48. G. Hornreich, U. Beller, O. Lavie et al., Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature, Gynecol Oncol 75 (1999), 300-304.
49. A. Howell, J. Cuzick, M. Baum et al., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet 365 (2005), 60-62.
50. E.S. Hwang, J.L. McLennan, D.H. Moore et al., Ductal Carcinoma In Situ in BRCA Mutation Carriers, J Clin Oncol 25 (2007), 642-647.
51. H. Jernstrom, C. Lerman, P. Ghadirian et al., Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2, Lancet 354 (1999), 1846-1850.
52. H. Jernstrom, J. Lubinski, H.T. Lynch et al., Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst 96 (2004), 1094-1098.
53. N. Kauff, Educational Session: Management of BRCA-Negative Hereditary Breast Cancer Families, in American Society of Clinical Oncology Annual Meeting, 2006: Atlanta, Georgia.
54. N. Kauff, M. Domcheck, T.M. Friebel et al., Multicenter prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA associated breast and ovarian cancer., Journal of Clinical Oncology - ASCO Annual Meeting Proceedings Part I 24 (2006), 1003.
55. N.D. Kauff, J.M. Satagopan, M.E. Robson et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med 346 (2002), 1609-1615.
56. N.D. Kauff, E. Brogi, L. Scheuer et al., Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations, Cancer 97 (2003), 1601-1608.
57. N.D. Kauff, N. Mitra, M.E. Robson et al., Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families, J Natl Cancer Inst 97 (2005), 1382-1384.
58. R.D. Kennedy, J.E. Quinn, P.B. Mullan et al., The role of BRCA1 in the cellular response to chemotherapy, J Natl Cancer Inst 96 (2004), 1659-1668.
59. K. Kerlikowske, D. Grady, S.M. Rubin et al., Efficacy of screening mammography. A meta-analysis, JAMA 273 (1995), 149-154.
60. M.C. King, S. Wieand, K. Hale et al., Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial, JAMA 286 (2001), 2251-2256.
61. Y.M. Kirova, D. Stoppa-Lyonnet, A. Savignoni et al., Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy, Eur J Cancer 41 (2005), 2304-2311.
62. I.K. Komenaka, B.A. Ditkoff, K.A. Joseph et al., The development of interval breast malignancies in patients with BRCA mutations, Cancer 100 (2004), 2079-2083.
63. Z. Kote-Jarai, T.J. Powles, G. Mitchell et al., BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial, Cancer Lett 247 (2006), 259-265.
64. J. Kotsopoulos, J. Lubinski, H.T. Lynch et al., Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, Cancer Causes Control 16 (2005), 667-674.
65. J.L. Kramer, I.A. Velazquez, B.E. Chen et al., Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers, J Clin Oncol 23 (2005), 8629-8635.
66. M. Kriege, C.T. Brekelmans, C. Boetes et al., Efficacy ofMRI and mammography for breast-cancer screening in women with a familial or genetic predisposition, N Engl J Med 351 (2004), 427-437.
67. M. Kriege, C.T. Brekelmans, I.M. Obdeijn et al., Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer, Breast Cancer Res Treat 100 (2006), 109-119.
68. C.K. Kuhl, S. Schrading, C.C. Leutner et al., Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer, J Clin Oncol 23 (2005), 8469-8476.
69. S.R. Lakhani, J. Jacquemier, J.P. Sloane et al., Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations, J Natl Cancer Inst 90 (1998), 1138-1145.
70. S.R. Lakhani, M.J. Van De Vijver, J. Jacquemier et al., The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2, J Clin Oncol 20 (2002), 2310-2318.
71. M.O. Leach, C.R. Boggis, A.K. Dixon et al., Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS), Lancet 365 (2005), 1769-1778.
72. C.D. Lehman, J.D. Blume, P. Weatherall et al., Screening women at high risk for breast cancer with mammography and magnetic resonance imaging, Cancer 103 (2005), 1898-1905.
73. D.A. Levine, O. Lin, R.R. Barakat et al., Risk of endometrial carcinoma associated with BRCA mutation, Gynecol Oncol 80 (2001), 395-398.
74. D.A. Levine, P.A. Argenta, C.J. Yee et al., Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations, J Clin Oncol 21 (2003), 4222-4227.
75. L. Liberman, Breast cancer screening with MRI - what are the data for patients at high risk?, N Engl J Med 351 (2004), 497-500.
76. C.L. Loprinzi, J.W. Kugler, J.A. Sloan et al., Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial, Lancet 356 (2000), 2059-2063.
77. J.B. Madalinska, J. Hollenstein, E. Bleiker et al., Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer, J Clin Oncol 23 (2005), 6890-6898.
78. J.N. Marcus, P. Watson, D.L. Page et al., Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage, Cancer 77 (1996), 697-709.
79. V.A. McCormack and I. dos Santos Silva, Breast density and parenchymal patterns as markers of breast cancer risk: A meta-analysis, Cancer Epidemiol Biomarkers Prev 15 (2006), 1159-1169.
80. J.R. McLaughlin, H.A. Risch, J. Lubinski et al., Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study, Lancet Oncol 8 (2007), 26-34.
81. H. Meijers-Heijboer, B. van Geel, W.L. van Putten et al., Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med 345 (2001), 159-164.
82. K. Metcalfe, H.T. Lynch, P. Ghadirian et al., Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers, J Clin Oncol 22 (2004), 2328-2335.
83. K.A. Metcalfe, J.L. Semple and S.A. Narod, Time to reconsider subcutaneous mastectomy for breast-cancer prevention? Lancet Oncol 6 (2005), 431-434.
84. G. Mitchell, A.C. Antoniou, R. Warren et al., Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers, Cancer Res 66 (2006), 1866-1872.
85. B. Modan, P. Hartge, G. Hirsh-Yechezkel et al., Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation, N Engl J Med 345 (2001), 235-240.
86. A. Munkarah, M. Chatterjee and M.A. Tainsky, Update on ovarian cancer screening, Curr Opin Obstet Gynecol 19 (2007), 22-26.
87. S.A. Narod, J.S. Brunet, P. Ghadirian et al., Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group, Lancet 356 (2000), 1876-1881.
88. S.A. Narod, M.P. Dube, J. Klijn et al., Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers, J Natl Cancer Inst 94 (2002), 1773-1779.
89. S.A. Narod, J. Lubinski, P. Ghadirian et al., Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study, Lancet Oncol 7 (2006), 402-406.
90. National Comprehensive Cancer Network, Genetic/Familial High-risk Assessment: Breast and Ovarian, National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - v.1.2006 cited 2006 September 1; Available from: http://www.nccn.org/professionals/ physician_gls/PDF/genetics_screening.pdf.
91. National Comprehensive Cancer Network, Breast Cancer Risk Reduction, National Comprehensive Cancer Network Clinical Practice Guidelines - v.1.2007 cited 2007 February 4; Available from: http://www.nccn.org/ professionals/physician_gls/PDF/breasts_rik.pdf
92. K.M. Newton, S.D. Reed, A.Z. LaCroix et al., Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial, Ann Intern Med 145 (2006), 869-879.
93. P.J. Paley, E.M. Swisher, R.L. Garcia et al., Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis, Gynecol Oncol 80 (2001), 176-180.
94. L.J. Pierce, M. Strawderman, S.A. Narod et al., Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations, J Clin Oncol 18 (2000), 3360-3369.
95. L.J. Pierce, A.M. Levin, T.R. Rebbeck et al., Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer, J Clin Oncol 24 (2006), 2437-2443.
96. S.K. Plevritis, A.W. Kurian, B.M. Sigal et al., Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging, JAMA 295 (2006), 2374-2384.
97. C.B. Powell, E. Kenley, L.M. Chen et al., Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy, J Clin Oncol 23 (2005), 127-132.
98. T. Powles, R. Eeles, S. Ashley et al., Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial, Lancet 352 (1998), 98-101.
99. T.R. Rebbeck, A.M. Levin, A. Eisen et al., Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers, J Natl Cancer Inst 91 (1999), 1475-1479.
100. T.R. Rebbeck, H.T. Lynch, S.L. Neuhausen et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, N Engl J Med 346 (2002), 1616-1622.
101. T.R. Rebbeck, T. Friebel, H.T. Lynch et al., Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group, J Clin Oncol 22 (2004), 1055-1062.
102. T.R. Rebbeck, T. Friebel, T. Wagner et al., Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group, J Clin Oncol 23 (2005), 7804-7810.
103. T.R. Rebbeck, A.B. Troxel, S. Norman et al., A retrospective case-control study of the use of hormone-related supplements and association with breast cancer, Int J Cancer 120 (2007), 1523-1528.
104. M. Robson, P. Rajan, P.P. Rosen et al., BRCA-associated breast cancer: Absence of a characteristic immunophenotype, Cancer Res 58 (1998), 1839-1842.
105. M. Robson, D. Levin, M. Federici et al., Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations, J Natl Cancer Inst 91 (1999), 2112-2117.
106. M. Robson, T. Svahn, B. McCormick et al., Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: A clinic-based series, Cancer 103 (2005), 44-51.
107. M.E. Robson, P.O. Chappuis, J. Satagopan et al., A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment, Breast Cancer Res 6 (2004), R8-R17.
108. M.E. Robson and K. Offit, Breast MRI for women with hereditary cancer risk, JAMA 292 (2004), 1368-1370.
109. F. Sardanelli, F. Podo, G. D'Agnolo et al., Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): Interim results, Radiology 242 (2007), 698-715.
110. L. Scheuer, N. Kauff, M. Robson et al., Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers, J Clin Oncol 20 (2002), 1260-1268.
111. M.D. Schwartz, E. Kaufman, B.N. Peshkin et al., Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing, J Clin Oncol 21 (2003), 4034-4041.
112. M.D. Schwartz, C. Lerman, B. Brogan et al., Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients, J Clin Oncol 22 (2004), 1823-1829.
113. M.D. Schwartz, C. Lerman, B. Brogan et al., Utilization of BRCA1/ BRCA2 mutation testing in newly diagnosed breast cancer patients, Cancer Epidemiol Biomarkers Prev 14 (2005), 1003-1007.
114. C. Seynaeve, L.C. Verhoog, L.M. van de Bosch et al., Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy, Eur J Cancer 40 (2004), 1150-1158.
115. K. Shahedi, M. Emanuelsson, F. Wiklund et al., High risk of contralateral breast carcinoma in women with hereditary/familial non- BRCA1/BRCA2 breast carcinoma, Cancer 106 (2006), 1237-1242.
116. S. Shanley, K. McReynolds, A. Ardern-Jones et al., Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom, Clin Cancer Res 12 (2006), 7025-7032.
117. S. Shanley, K. McReynolds, A. Ardern-Jones et al., Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom, Clin Cancer Res 12 (2006), 7033-7038.
118. S. K. Sharan, M. Morimatsu, U. Albrecht et al., Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2, Nature 386 (1997), 804-810.
119. B.L. Sicat and D.K. Brokaw, Nonhormonal alternatives for the treatment of hot flashes, Pharmacotherapy 24 (2004), 79-93.
120. A.J. Stolier and R.L. Corsetti, Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation, Am Surg 71 (2005), 1031-1033.
121. D. Stoppa-Lyonnet, Y. Ansquer, H. Dreyfus et al., Familial invasive breast cancers: Worse outcome related to BRCA1 mutations, J Clin Oncol 18 (2000), 4053-4059.
122. K.P. Tercyak, B.N. Peshkin, B.M. Brogan et al., Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing, J Clin Oncol 25 (2007), 285-291.
123. D. Thompson, S. Duedal, J. Kirner et al., Cancer risks and mortality in heterozygous ATMmutation carriers, J Natl Cancer Inst 97 (2005), 813-822.
124. M. Tilanus-Linthorst, L. Verhoog, I.M. Obdeijn et al., A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography, Int J Cancer 102 (2002), 91-95.
125. M.M. Tilanus-Linthorst, I.M. Obdeijn, K.C. Bartels et al., First experiences in screening women at high risk for breast cancer with MR imaging, Breast Cancer Res Treat 63 (2000), 53-60.
126. M.M. Tilanus-Linthorst, M. Kriege, C. Boetes et al., Hereditary breast cancer growth rates and its impact on screening policy, Eur J Cancer 41 (2005), 1610-1617.
127. A. Trepanier, M. Ahrens,W. McKinnon et al., Genetic cancer risk assessment and counseling: Recommendations of the national society of genetic counselors, J Genet Couns 13 (2004), 83-114.
128. B.C. Turner, E. Harrold, E. Matloff et al., BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations, J Clin Oncol 17 (1999), 3017-3024.
129. L.C. Verhoog, C.T. Brekelmans, C. Seynaeve et al., Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1, Lancet 351 (1998), 316-321.
130. L.C. Verhoog, C.T. Brekelmans, C. Seynaeve et al., Survival in hereditary breast cancer associated with germline mutations of BRCA2, J Clin Oncol 17 (1999), 3396-3402.
131. L.C. Verhoog, E.M. Berns, C.T. Brekelmans et al., Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients, J Clin Oncol 18 (2000), 119S-124S.
132. U. Veronesi, P. Maisonneuve, A. Costa et al., Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study, Lancet 352 (1998), 93-97.
133. V.G. Vogel, J.P. Costantino, D.L. Wickerham et al., Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial, JAMA 295 (2006), 2727-2741.
134. T. Walsh, S. Casadei, K.H. Coats et al., Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer, JAMA 295 (2006), 1379-1388.
135. E. Warner, D.B. Plewes, K.A. Hill et al., Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination, JAMA 292 (2004), 1317-1325.
136. E. Warner and P.A. Causer, MRI surveillance for hereditary breast-cancer risk, Lancet 365 (2005), 1747-1749.
137. M. Weischer, S.E. Bojesen, A. Tybjaerg-Hansen et al., Increased risk of breast cancer associated with CHEK2* 1100delC, J Clin Oncol 25 (2007), 57-63.
138. J.N. Weitzel, M. Robson, B. Pasini et al., A comparison of bilateral breast cancers in BRCA carriers, Cancer Epidemiol Biomarkers Prev 14 (2005), 1534-1538.